US Patent

US9623014 — β-lactamase inhibitor compounds

Method of Use · Assigned to Entasis Therapeutics Ltd · Expires 2033-04-02 · 7y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects beta-lactamase inhibitor compounds, including their salts, for use in treating bacterial infections, including those caused by drug-resistant organisms.

USPTO Abstract

The present invention is directed to compounds which are beta-lacatamase inhibitors. The compounds and their pharmaceutically acceptable salts, are useful in combination with beta-lactam antibiotics, or alone, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to formula (Ia): or a pharmaceutically acceptable salt thereof, wherein the values of R 1 , R 2 , R 3 and R 4 are described herein.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2840 — durlobactam-sodium

Patent Metadata

Patent number
US9623014
Jurisdiction
US
Classification
Method of Use
Expires
2033-04-02
Drug substance claim
No
Drug product claim
No
Assignee
Entasis Therapeutics Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.